ATE192922T1 - Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden - Google Patents

Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden

Info

Publication number
ATE192922T1
ATE192922T1 AT95900491T AT95900491T ATE192922T1 AT E192922 T1 ATE192922 T1 AT E192922T1 AT 95900491 T AT95900491 T AT 95900491T AT 95900491 T AT95900491 T AT 95900491T AT E192922 T1 ATE192922 T1 AT E192922T1
Authority
AT
Austria
Prior art keywords
reperfusion injury
medicinal
production
nitrogen oxide
protect against
Prior art date
Application number
AT95900491T
Other languages
English (en)
Inventor
David A Wink Jr
James B Mitchell
Angelo Russo
Murali C Krishna
Ingeborg Hanbauer
Matthew B Grisham
Daniel Neil Granger
Original Assignee
Us Health
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Univ Louisiana State filed Critical Us Health
Application granted granted Critical
Publication of ATE192922T1 publication Critical patent/ATE192922T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT95900491T 1993-11-02 1994-10-31 Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden ATE192922T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14661093A 1993-11-02 1993-11-02
PCT/US1994/012510 WO1995012394A1 (en) 1993-11-02 1994-10-31 Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury

Publications (1)

Publication Number Publication Date
ATE192922T1 true ATE192922T1 (de) 2000-06-15

Family

ID=22518169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900491T ATE192922T1 (de) 1993-11-02 1994-10-31 Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden

Country Status (12)

Country Link
US (1) US5789447A (de)
EP (1) EP0726768B1 (de)
JP (1) JPH09508097A (de)
AT (1) ATE192922T1 (de)
AU (1) AU704173B2 (de)
CA (1) CA2175467A1 (de)
DE (1) DE69424560T2 (de)
DK (1) DK0726768T3 (de)
ES (1) ES2149338T3 (de)
GR (1) GR3034099T3 (de)
PT (1) PT726768E (de)
WO (1) WO1995012394A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US6190704B1 (en) * 1994-09-23 2001-02-20 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Regulation of wound healing by nitric oxide
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
ES2267141T3 (es) * 1996-04-05 2007-03-01 The General Hospital Corporation Tratamiento de una hemoglobinopatia.
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
AU1770299A (en) * 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
ES2147162B1 (es) 1999-01-27 2001-03-16 Lacer Sa "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
EP1233670B1 (de) * 1999-06-14 2008-09-17 Henry Ford Health System Stickstoffmonoxid-donoren zum induzieren von neurogenese
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6811965B2 (en) * 2000-03-08 2004-11-02 Yoram Vodovotz Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use
US6270779B1 (en) * 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
FR2812200B1 (fr) * 2000-07-27 2003-01-03 Oxykines Therapeutics Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote ; et utilisations
KR20030065463A (ko) * 2000-08-11 2003-08-06 데이비드 알. 휘트록 질소 산화물 및 질소 산화물 전구체의 생산을 증가시키기위한 암모니아 산화 박테리아를 포함하는 조성물 및 이를이용하는 방법
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
WO2003026717A1 (en) * 2001-09-26 2003-04-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
CN1308438C (zh) * 2002-01-11 2007-04-04 大卫·R·怀特洛克 含有氨氧化细菌的化合物以及使用的方法
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
WO2004017939A1 (ja) * 2002-08-20 2004-03-04 Terumo Kabushiki Kaisha 体内埋込医療器具
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
US20050009789A1 (en) * 2003-05-13 2005-01-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service Cyclooxygenase inhibition with nitroxyl
JP5564158B2 (ja) 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
EP1667646A4 (de) * 2003-09-26 2007-07-04 David R Whitlock Verfahren zur verwendung von ammoniak-oxidierenden bakterien
US20080085329A1 (en) * 2003-10-22 2008-04-10 Fred Hutchinson Cancer Research Center, Inc. Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
JP4738352B2 (ja) 2004-02-09 2011-08-03 アミュレット ファーマシューティカルズ インコーポレイティッド 一酸化窒素放出ポリマー
US20070232996A1 (en) * 2004-04-29 2007-10-04 Cube Medical A/S Balloon for Use in Angioplasty with an Outer Layer of Nanofibers
US20080029093A1 (en) * 2004-05-11 2008-02-07 Alex Stenzler Intermittent Dosing Of Nitric Oxide Gas
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
CA2605631A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP1888510A4 (de) 2005-05-27 2013-01-16 Univ North Carolina Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
US20090298795A1 (en) * 2005-06-23 2009-12-03 The Johns Hopins University Thiol-Sensitive Positive Inotropes
US20070116785A1 (en) * 2005-11-18 2007-05-24 Miller Christopher C Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
EP1968615A4 (de) * 2005-12-06 2010-08-04 Amulet Pharmaceuticals Inc Stickoxid freisetzende polymere
AU2014201936B2 (en) * 2006-10-06 2016-07-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
EP3424950A1 (de) 2006-10-06 2019-01-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prävention von gewebeischämie, damit in zusammenhang stehende verfahren und zusammensetzungen
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
EP1939179A1 (de) 2006-12-28 2008-07-02 Lacer, S.A. Stabile S-Nitrosothiole, Syntheseverfahren und Verwendung
WO2008089282A2 (en) * 2007-01-16 2008-07-24 Silver James H Sensors for detecting subtances indicative of stroke, ischemia, infection or inflammation
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
US20080269109A1 (en) * 2007-04-30 2008-10-30 Becker Lance B System and method of resuscitation of a mammal
EP2237788A4 (de) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc Aerosolisierte nitrit- und stickoxidspendende verbindungen und ihre verwendung
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
AU2010328234B2 (en) * 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
CN105130855B (zh) * 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
US20140088034A1 (en) * 2011-05-11 2014-03-27 Stc.Unm NITRIC OXIDE/cGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
KR20210100224A (ko) 2014-04-15 2021-08-13 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
US10662063B1 (en) * 2016-06-06 2020-05-26 University Of Puerto Rico Photosensitized release of nitric oxide
EP3523367A4 (de) 2016-10-07 2020-06-03 The University Of North Carolina At Chapel Hill S-nitrosothiol-vermittelte hyperverzweigte polyester
US11072668B2 (en) 2017-01-03 2021-07-27 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
JP7403152B2 (ja) 2017-03-28 2023-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景
AU2018369760B2 (en) 2017-11-15 2025-01-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7645546B2 (ja) 2018-12-28 2025-03-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153094A (en) * 1959-06-10 1964-10-13 Du Pont Nitrosamine manufacture
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs

Also Published As

Publication number Publication date
ES2149338T3 (es) 2000-11-01
GR3034099T3 (en) 2000-11-30
CA2175467A1 (en) 1995-05-11
AU8130094A (en) 1995-05-23
AU704173B2 (en) 1999-04-15
US5789447A (en) 1998-08-04
JPH09508097A (ja) 1997-08-19
PT726768E (pt) 2000-11-30
DE69424560D1 (de) 2000-06-21
DE69424560T2 (de) 2001-01-18
EP0726768A1 (de) 1996-08-21
WO1995012394A1 (en) 1995-05-11
EP0726768B1 (de) 2000-05-17
DK0726768T3 (da) 2000-10-02

Similar Documents

Publication Publication Date Title
ATE192922T1 (de) Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden
ATE194769T1 (de) Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
NO176566C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive aminosyrederivater
DE69331643D1 (de) Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
EP0449247A3 (en) Pharmaceutical composition containing galanthamine for treating alcoholism
ATE174514T1 (de) Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
ATE270553T1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
DE69327330D1 (de) Verfahren zum bekämpfen der pneumocystis carinii pneumonie und dafür verwendbare verbindungen
ATE84721T1 (de) Physiologisch wirksame produkte, verfahren zur herstellung und zusammensetzung.
ATE211729T1 (de) Therapeutisch wirksame verbindungen
DE3581416D1 (de) Arzneimittel und die verwendung schwerloeslicher calcium- und/oder magnesiumverbindungen zur herstellung eines arzneimittels.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
MY104521A (en) Treatment of depression.
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
YU56702A (sh) Korišćenje fsh za lečenje neplodnosti
ES2101100T3 (es) Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura.
ATE102955T1 (de) Zyklisches tetrapeptid und verfahren zu dessen herstellung.
TR200102009T2 (tr) Serebral işlemi profilaksı ve tedavisi için formül I&#39;e göre bileşiklerin kullanımı
JPS5536453A (en) Novel immunosuppressive agent
ATE170400T1 (de) Verwendung von trovafloxacin oder dessen derivaten zur herstellung eines arzneimittels zur behandlung von h.pylori infektionen
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
ES456280A1 (es) Un procedimiento para la obtencion de alfa-2,5,9-trimetil- benzo(b)tieno(2,3-f)morfano.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee